These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 7585510)

  • 1. Suppression of growth of renal carcinoma cells by the von Hippel-Lindau tumor suppressor gene.
    Chen F; Kishida T; Duh FM; Renbaum P; Orcutt ML; Schmidt L; Zbar B
    Cancer Res; 1995 Nov; 55(21):4804-7. PubMed ID: 7585510
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinomas.
    Shuin T; Kondo K; Torigoe S; Kishida T; Kubota Y; Hosaka M; Nagashima Y; Kitamura H; Latif F; Zbar B
    Cancer Res; 1994 Jun; 54(11):2852-5. PubMed ID: 8187067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of the promoter of the human von Hippel-Lindau disease tumor suppressor gene.
    Kuzmin I; Duh FM; Latif F; Geil L; Zbar B; Lerman MI
    Oncogene; 1995 Jun; 10(11):2185-94. PubMed ID: 7784063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutations of the VHL tumour suppressor gene in renal carcinoma.
    Gnarra JR; Tory K; Weng Y; Schmidt L; Wei MH; Li H; Latif F; Liu S; Chen F; Duh FM
    Nat Genet; 1994 May; 7(1):85-90. PubMed ID: 7915601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of von Hippel-Lindau disease gene mutations in paraffin-embedded sporadic renal cell carcinoma specimens.
    Zhuang Z; Gnarra JR; Dudley CF; Zbar B; Linehan WM; Lubensky IA
    Mod Pathol; 1996 Aug; 9(8):838-42. PubMed ID: 8871925
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cloning and characterization of a mouse gene with homology to the human von Hippel-Lindau disease tumor suppressor gene: implications for the potential organization of the human von Hippel-Lindau disease gene.
    Gao J; Naglich JG; Laidlaw J; Whaley JM; Seizinger BR; Kley N
    Cancer Res; 1995 Feb; 55(4):743-7. PubMed ID: 7850784
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular cytogenetic characterization of early and late renal cell carcinomas in von Hippel-Lindau disease.
    Phillips JL; Ghadimi BM; Wangsa D; Padilla-Nash H; Worrell R; Hewitt S; Walther M; Linehan WM; Klausner RD; Ried T
    Genes Chromosomes Cancer; 2001 May; 31(1):1-9. PubMed ID: 11284029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential susceptibility of renal carcinoma cell lines to tumor suppression by exogenous Fhit expression.
    Werner NS; Siprashvili Z; Fong LY; Marquitan G; Schröder JK; Bardenheuer W; Seeber S; Huebner K; Schütte J; Opalka B
    Cancer Res; 2000 Jun; 60(11):2780-5. PubMed ID: 10850413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reversion of deregulated expression of vascular endothelial growth factor in human renal carcinoma cells by von Hippel-Lindau tumor suppressor protein.
    Siemeister G; Weindel K; Mohrs K; Barleon B; Martiny-Baron G; Marmé D
    Cancer Res; 1996 May; 56(10):2299-301. PubMed ID: 8625303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Von Hippel-Lindau disease maps to the region of chromosome 3 associated with renal cell carcinoma.
    Seizinger BR; Rouleau GA; Ozelius LJ; Lane AH; Farmer GE; Lamiell JM; Haines J; Yuen JW; Collins D; Majoor-Krakauer D
    Nature; 1988 Mar; 332(6161):268-9. PubMed ID: 2894613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of the actin regulator HSPC300 results in clear cell renal cell carcinoma protection in Von Hippel-Lindau patients.
    Cascón A; Escobar B; Montero-Conde C; Rodríguez-Antona C; Ruiz-Llorente S; Osorio A; Mercadillo F; Letón R; Campos JM; García-Sagredo JM; Benítez J; Malumbres M; Robledo M
    Hum Mutat; 2007 Jun; 28(6):613-21. PubMed ID: 17311301
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alternate choice of initiation codon produces a biologically active product of the von Hippel Lindau gene with tumor suppressor activity.
    Blankenship C; Naglich JG; Whaley JM; Seizinger B; Kley N
    Oncogene; 1999 Feb; 18(8):1529-35. PubMed ID: 10102622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Germ-line mutations in the von Hippel-Lindau tumor-suppressor gene are similar to somatic von Hippel-Lindau aberrations in sporadic renal cell carcinoma.
    Whaley JM; Naglich J; Gelbert L; Hsia YE; Lamiell JM; Green JS; Collins D; Neumann HP; Laidlaw J; Li FP
    Am J Hum Genet; 1994 Dec; 55(6):1092-102. PubMed ID: 7977367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The von Hippel-Lindau tumor suppressor gene inhibits hepatocyte growth factor/scatter factor-induced invasion and branching morphogenesis in renal carcinoma cells.
    Koochekpour S; Jeffers M; Wang PH; Gong C; Taylor GA; Roessler LM; Stearman R; Vasselli JR; Stetler-Stevenson WG; Kaelin WG; Linehan WM; Klausner RD; Gnarra JR; Vande Woude GF
    Mol Cell Biol; 1999 Sep; 19(9):5902-12. PubMed ID: 10454537
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutated Von Hippel-Lindau-renal cell carcinoma (RCC) promotes patients specific natural killer (NK) cytotoxicity.
    Trotta AM; Santagata S; Zanotta S; D'Alterio C; Napolitano M; Rea G; Camerlingo R; Esposito F; Lamantia E; Anniciello A; Botti G; Longo N; Botti G; Pignata S; Perdonà S; Scala S
    J Exp Clin Cancer Res; 2018 Dec; 37(1):297. PubMed ID: 30514329
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MicroRNA-185 inhibits cell proliferation and induces cell apoptosis by targeting VEGFA directly in von Hippel-Lindau-inactivated clear cell renal cell carcinoma.
    Ma X; Shen D; Li H; Zhang Y; Lv X; Huang Q; Gao Y; Li X; Gu L; Xiu S; Bao X; Duan J; Zhang X
    Urol Oncol; 2015 Apr; 33(4):169.e1-11. PubMed ID: 25700976
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel mutations of the von hippel-lindau tumor-suppressor gene and rare DNA hypermethylation in renal-cell carcinoma cell lines of the clear-cell type.
    Meyer AJ; Hernandez A; Florl AR; Enczmann J; Gerharz CD; Schulz WA; Wernet P; Ackermann R
    Int J Cancer; 2000 Sep; 87(5):650-3. PubMed ID: 10925357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. VHL expression in renal cell carcinoma sensitizes to bortezomib (PS-341) through an NF-kappaB-dependent mechanism.
    An J; Fisher M; Rettig MB
    Oncogene; 2005 Feb; 24(9):1563-70. PubMed ID: 15608669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumour suppression by the human von Hippel-Lindau gene product.
    Iliopoulos O; Kibel A; Gray S; Kaelin WG
    Nat Med; 1995 Aug; 1(8):822-6. PubMed ID: 7585187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. von Hippel-Lindau gene-mediated growth suppression and induction of differentiation in renal cell carcinoma cells grown as multicellular tumor spheroids.
    Lieubeau-Teillet B; Rak J; Jothy S; Iliopoulos O; Kaelin W; Kerbel RS
    Cancer Res; 1998 Nov; 58(21):4957-62. PubMed ID: 9810005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.